CClinicalTrials.gg
Not yet recruitingNCT07272863Updated May 8, 2026

The Impact of Brief Behavioral Treatment for Insomnia Versus Brief Mindfulness Treatment on Cognition and Sleep Health in Adults (Age 50+) With HIV

An interventional study of BBTI and BMT in Insomnia, Cognition and Aging, sponsored by University of Alabama, Tuscaloosa. Not yet recruiting at 2 sites in United States. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University of Alabama, Tuscaloosa · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
50 Years to 99 Years
Sex
All
01

Study summary

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are:

What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT?

Participants will:

  • Complete 4 weeks of telephone-delivered BBTI or BMT
  • Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments
  • Have blood collected at all three time points
02

Conditions studied

  • Insomnia
  • Cognition
  • Aging
  • HIV

Keywords

  • insomnia
  • cognition
  • older adults
  • HIV
  • Alzheimer's Disease
  • brief behavioral treatment
  • randomized control trial
03

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • must be age 50 or older
  • have a DSM-5 diagnostic criteria for insomnia including sleep difficulty that occurs at least 3 times per week and has been a problem for at least 3 consecutive months (indicated on the Structured Clinical Interview for Sleep Disorders, SCISD) during telephone screening
  • have a confirmed HIV diagnosis and a prescribed ART regimen for at least 12 months.

Exclusion criteria

Exclusion Criteria:

  • unable to speak English
  • have a reported or documented (in medical records) diagnosis of AD or dementia
  • have severe neurocognitive impairment (>7 errors on the Short Portable Mental Status Questionnaire, SPMSQ) during telephone screening
  • have a history of a stroke
  • currently undergoing radiation/chemotherapy
  • reports a history of brain trauma with loss of consciousness greater than 30 minutes
  • have a learning disability
  • have a documented diagnosis of sleep apnea (in medical records)
  • reports use of a continuous positive airway pressure machine
  • have been identified as high risk for moderate to severe sleep apnea (Snoring, Tiredness, Observed sleep apnea, Pressure, BMI, Age, Neck circumference, and Gender, STOP BANG ≥ 5) during telephone screening
  • have restless leg syndrome and/or have narcolepsy
  • have a documented history of bipolar disorder or psychotic disorder
  • not be receiving efavirenz as part of their current ART regimen
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
214 participants (estimated)

Study arms

  • Experimental
    Brief Behavioral Treatment for Insomnia (BBTI)

    Behavioral: BBTI

  • Active comparator
    Brief Mindfulness Treatment (BMT)

    Behavioral: BMT

Interventions

  • BehavioralBBTI

    4-week intervention delivered via telephone (once a week for 30 minutes)

  • BehavioralBMT

    4-week intervention delivered via telephone (once a week for 30 minutes)

05

What researchers measure

Primary outcomes

  1. Insomnia Severity Index

    Assesses insomnia severity symptoms with scores ranging from 0 - 28. Scores of 0-7 indicate no clinically significant insomnia; scores 8-14 indicate mild insomnia; scores 15-21 indicate moderate insomnia; scores 22-28 indicate severe insomnia

    Time frame: From enrollment until 1-year post-intervention

  2. 7-day Sleep Actigraphy

    Actigraphy will be conducted at (baseline, post-intervention. and 1-year post intervention) to obtain objective sleep data including total sleep time, falling asleep time, wake-up time, sleep latency, awakenings after sleep onset, and sleep efficiency.

    Time frame: From enrollment until 1-year post-intervention

  3. Consensus Sleep Diaries

    The diaries will be completed twice a day (before going to bed at night, and then the following morning) in conjunction with the actigraphy measurement of their sleep to improve the quality of the actigraphy data.

    Time frame: From enrollment until 1-year post-intervention

  4. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Consists of 12 subtests measuring five domains: Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory. RBANS has four equivalent alternate test forms. Total scores range from 40 to 160, with higher scores indicating better cognitive function

    Time frame: From enrollment until 1-year post-intervention

  5. Delis-Kaplan Executive Function System (D-KEFS)

    Three D-KEFS tests will be used for this study: Trail Making Test, Verbal Fluency Test, and Color-Word Interference Test.

    Time frame: From enrollment until 1-year post-intervention

  6. Patient's Assessment of Own Functioning Inventory (PAOFI)

    Measures the effects of cognitive abilities on everyday activities. Scores are summed from each domain for a total score ranging from 0 to 50, with higher scores indicated worse perceived everyday functioning.

    Time frame: From enrollment until 1-year post-intervention

  7. Pittsburgh Sleep Quality Index (PSQI)

    An 18-item questionnaire used to assess sleep quality. Scores from 7 components are summed for a global PSQI score range from 0-21, with higher scores (\> 5) indicating poorer quality of sleep.

    Time frame: From enrollment until 1-year post-intervention

Secondary outcomes

  1. Amyloid beta (Aβ42/40)

    Aβ42/40 ratio is a marker of amyloid plaque accumulation which is a hallmark of Alzheimer's Disease

    Time frame: From enrollment until 1-year post-intervention

  2. P-tau

    Biomarker for identifying individuals at risk for Alzheimer's Disease

    Time frame: From enrollment until 1-year post-intervention

06

Study locations

2 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    • Dr. Stephen Justin Thomas, PhD, DBSM, FSBSM · Contact · sjthoma@uabmc.edu · 205 934 3367
    • Dr. David E. Vance, PhD, MGS, FAAN · Contact · devance@uab.edu · 205 934 7589
    • Dr. Shu Chen, PhD · Sub investigator
  • The University of Alabama
    Tuscaloosa, Alabama 35401, United States
    • Dr. Shameka L. Cody, PhD, AGNP-C, PMHNP-BC, FAAN · Contact · slcody@ua.edu · 205 348 3374
    • Dr. Mary L. Jacobs, PhD, MSPH, ABPP · Contact · jacob008@ua.edu
    • Dr. Chuong Bui, PhD · Sub investigator
07

References and documents

Publications

  • Cody SL, Kusko DA, Gonzalez CE, Owens MA, Hobson JM, Gilstrap SR, Thomas SJ, Goodin BR. Improving Sleep in People with HIV and Chronic Pain: A Pilot Study of Brief Behavioral Treatment for Insomnia. Behav Sleep Med. 2024 Nov-Dec;22(6):949-959. doi: 10.1080/15402002.2024.2396820. Epub 2024 Sep 8. PubMed 39244666 ↗

Individual participant data

Plan to share: No — The data and associated documentation will be made available to users only under a data-sharing agreement that provides for: (1) a commitment to use the data only for research purposes and not to identify any individual person; (2) a commitment to secure the data using appropriate computer technology; and (3) a commitment to destroy or return the data after analyses are completed. Although it is assumed that most users will want either a SAS or SPSS file, we have the ability to translate data sets into several other formats and will provide one of these if requested by a user

08

Registry details

Key details

Study ID
NCT07272863
Lead sponsor
University of Alabama, Tuscaloosa
Collaborators
University of Alabama at Birmingham, National Institute on Aging (NIA), NIH Office of AIDS Research (OAR)
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
May 2026 (estimated)
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
May 8, 2026

Study contacts

Dr. Shameka L. Cody, PhD, AGNP-C, PMHNP-BC, FAAN
Contact
slcody@ua.edu
205 348 3374
Dr. Stephen Justin Thomas, PhD, DBSM, FSBSM
Contact
sjthoma@uabmc.edu
205 934 3367
Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN
principal investigator · The University of Alabama Capstone College of Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion